2020
Perniosis during the COVID‐19 pandemic: Negative anti‐SARS‐CoV‐2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS‐CoV‐2
Ko CJ, Harigopal M, Damsky W, Gehlhausen JR, Bosenberg M, Patrignelli R, McNiff JM. Perniosis during the COVID‐19 pandemic: Negative anti‐SARS‐CoV‐2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS‐CoV‐2. Journal Of Cutaneous Pathology 2020, 47: 997-1002. PMID: 32745281, PMCID: PMC7436569, DOI: 10.1111/cup.13830.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 nucleocapsid proteinPerivascular lymphocytesImmunohistochemical stainingCOVID-19 pandemicSARS-CoV-2 immunohistochemistryNucleocapsid proteinSARS-CoV-2Inflammatory lesionsHistopathologic findingsIntravascular occlusionMicroscopic findingsPerniosisIntravascular materialLymphocytesLesionsPatientsStainingPandemicSuch casesCuffingHistopathologyCasesImmunohistochemistryFindingsProtein
2014
p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma
Alomari AK, Glusac EJ, McNiff JM. p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma. Journal Of Cutaneous Pathology 2014, 41: 839-845. PMID: 25263848, DOI: 10.1111/cup.12388.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaAtypical fibroxanthomaCell carcinomaNon-cutaneous squamous-cell carcinomaNuclear stainingNon-squamous tumorsGiant cell tumorCutaneous leiomyosarcomaExclusive nuclear stainingCell tumorsDiagnostic challengeCytokeratin MNF116Focal stainingMNF116Tumor cytoplasmLeiomyosarcomaDiagnostic accuracyControl casesSoft tissueSpecific markersP40StainingCarcinomaP63Tumors